FDA approves Omalizumab (Xolair) to reduce food allergy reactions. Effective in trial subjects with multiple allergies, blocks allergic responses by binding immunoglobulin E. Not universal cure, continued vigilance required. Long-term effectiveness and combination with oral immunotherapy being researched. Side effects include injection reactions, fever, potential pain, infections, malignancies.

New FDA-approved drug makes severe food allergies less life-threatening Ars Technica

SoftBank founder Masayoshi Son aims to raise $100 billion for new chip venture, Project Izanagi, planning to rival Nvidia in AI processors and contribute to artificial general intelligence (AGI) development. It remains uncertain whether AI processors designed by Project Izanagi will use technologies such as instruction set architecture developed by Arm. How the new venture will co-exist with Arm's supposed plans to create reference chip designs for various workloads is also unclear. Son intends to invest $30 billion from SoftBank, with the remaining $70 billion potentially raised from Middle Eastern institutions. The specifics of Izanagi's funding and execution are still determined.

Softbank founder reportedly aims to raise $100 billion to build AI chip company that would rival Nvidia — Project Izanagi might leverage Arm design Tom's Hardware

Ukrainian Vyacheslav Igorevich Penchukov pleads guilty in US court for leading two cyber attack schemes causing millions in losses and crippling Vermont hospital in 2020, says Justice Department. Scheme began in 2009, involving infecting corporation computers with malware, collecting online banking login details, acting as corporation employees to transfer money, causing millions in losses. Arrested in Switzerland in 2022, extradited to US in 2023.

‘Most Wanted’ Man Pleads Guilty in Cyberattack That Upended Vermont Hospital New York Times

Insurers anticipate profit surge from Medicare and Medicaid eligibles despite high healthcare costs. Shift sees profits from government plans like Medicare Advantage and Medicaid managed care. McKinsey report predicts earnings from "dual eligibles" to grow >10% by 2027. 12-13m utilize both Medicare and Medicaid, 29% in private Medicare Advantage plan. Income <$20,000 for 87% dual enrollees and majority low-income, with different health needs.

Why health insurers suddenly want sicker patients Axios